CA2584333A1 - Compositions pharmaceutiques neuroprotectrices contenant du spirostenol - Google Patents

Compositions pharmaceutiques neuroprotectrices contenant du spirostenol Download PDF

Info

Publication number
CA2584333A1
CA2584333A1 CA002584333A CA2584333A CA2584333A1 CA 2584333 A1 CA2584333 A1 CA 2584333A1 CA 002584333 A CA002584333 A CA 002584333A CA 2584333 A CA2584333 A CA 2584333A CA 2584333 A1 CA2584333 A1 CA 2584333A1
Authority
CA
Canada
Prior art keywords
cells
hydroxycholesterol
alkyl
neuronal
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002584333A
Other languages
English (en)
Inventor
Zhi-Xing Yao
Laurent Lecanu
Gary Teper
Janet Greeson
Vassilios Papadopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Samaritan Pharmaceuticals Inc
Original Assignee
Georgetown University
Samaritan Pharmaceuticals, Inc.
Zhi-Xing Yao
Laurent Lecanu
Gary Teper
Janet Greeson
Vassilios Papadopoulos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/031,538 external-priority patent/US20060009433A1/en
Application filed by Georgetown University, Samaritan Pharmaceuticals, Inc., Zhi-Xing Yao, Laurent Lecanu, Gary Teper, Janet Greeson, Vassilios Papadopoulos filed Critical Georgetown University
Publication of CA2584333A1 publication Critical patent/CA2584333A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
CA002584333A 2004-10-14 2005-10-14 Compositions pharmaceutiques neuroprotectrices contenant du spirostenol Abandoned CA2584333A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61869604P 2004-10-14 2004-10-14
US60/618,696 2004-10-14
US11/031,538 2005-01-07
US11/031,538 US20060009433A1 (en) 2003-03-14 2005-01-07 Neuroprotective spirostenol pharmaceutical compositions
PCT/US2005/037023 WO2006044665A2 (fr) 2004-10-14 2005-10-14 Compositions pharmaceutiques neuroprotectrices contenant du spirostenol

Publications (1)

Publication Number Publication Date
CA2584333A1 true CA2584333A1 (fr) 2006-04-27

Family

ID=36203560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002584333A Abandoned CA2584333A1 (fr) 2004-10-14 2005-10-14 Compositions pharmaceutiques neuroprotectrices contenant du spirostenol

Country Status (5)

Country Link
EP (1) EP1809298A4 (fr)
JP (1) JP2008516972A (fr)
AU (1) AU2005295617A1 (fr)
CA (1) CA2584333A1 (fr)
WO (1) WO2006044665A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603127A1 (fr) * 2005-04-01 2006-10-12 Samaritan Pharmaceuticals, Inc. Utilisation de spirostenols dans le traitement des troubles mitochondriaux
GB0619860D0 (en) * 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2015163318A1 (fr) * 2014-04-25 2015-10-29 レジリオ株式会社 Agent thérapeutique pour des maladies associées à un dysfonctionnement des axones nerveux, comprenant un agent thérapeutique pour la maladie d'alzheimer
WO2024024395A1 (fr) * 2022-07-29 2024-02-01 国立大学法人富山大学 Composition pharmaceutique ou sous forme d'aliment et de boisson pour la prévention ou le traitement d'un trouble du nerf optique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
DE69929177T2 (de) * 1998-03-26 2006-08-24 Phytopharm Plc, Godmanchester Smilagenin und anzurogenin-d zur behandlung der alzheimerischen krankheit
GB0019290D0 (en) * 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
AU2003218180B2 (en) * 2002-03-15 2008-03-20 Georgetown University Neuroprotective spirostenol pharmaceutical compositions
WO2003086411A1 (fr) * 2002-04-15 2003-10-23 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Composes et techniques de preparation de carboxylate de diosgenine et d'un derive de succinate monoester de diosgenine

Also Published As

Publication number Publication date
JP2008516972A (ja) 2008-05-22
AU2005295617A1 (en) 2006-04-27
EP1809298A4 (fr) 2008-06-18
WO2006044665A3 (fr) 2007-07-05
EP1809298A2 (fr) 2007-07-25
WO2006044665A2 (fr) 2006-04-27

Similar Documents

Publication Publication Date Title
US20060009433A1 (en) Neuroprotective spirostenol pharmaceutical compositions
Zhang et al. Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia
JP4667363B2 (ja) ミフェプリストンおよびその誘導体のヘッジホッグタンパク質シグナリング経路調節剤としての新規な使用ならびにその適用
US20100178277A1 (en) Methods and compositions for stimulating cells
AU2003218180B2 (en) Neuroprotective spirostenol pharmaceutical compositions
Brimson et al. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
CN102159215B (zh) 使用TrkB激动剂治疗各种病症
EP3570940B1 (fr) Pridopidine pour utilisation pour traiter le syndrome de l'x fragile
CA2584333A1 (fr) Compositions pharmaceutiques neuroprotectrices contenant du spirostenol
Chen et al. Retracted: Allopregnanolone restores the tyrosine hydroxylase‐positive neurons and motor performance in a 6‐OHDA‐injected mouse model
US11065263B2 (en) Sterol composition in pumpkin seed oil and application thereof, and drug for treating benign prostatic hyperplasia
CN102727501A (zh) 皂角苷配基及其衍生物的用途
US20230364076A1 (en) Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
KR20210074901A (ko) 진세노사이드 Rg2, Rg4, Rg6, Rh1 및 Rh4를 유효성분으로 포함하는 근육 질환 예방 또는 치료용 약학 조성물
Zhu et al. Neuroprotection and enhancement of remyelination by estradiol and dexamethasone in cocultures of rat DRG neurons and Schwann cells
Yao et al. 22R-Hydroxycholesterol induces differentiation of human NT2 precursor (Ntera2/D1 teratocarcinoma) cells
CN105878229A (zh) 甘松萍瑚烷型倍半萜化合物的新用途
RU2814327C1 (ru) ПРИМЕНЕНИЕ СУЛЬФАТНЫХ СОЛЕЙ N-(3-(4-(3-(ДИИЗОБУТИЛАМИНО)ПРОПИЛ)ПИПЕРАЗИН-1-ИЛ)ПРОПИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛ-2-АМИНА И ИХ СОЛЬВАТОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДВИГАТЕЛЬНЫХ НЕЙРОНОВ И НАРУШЕНИЙ НЕРВНО-МЫШЕЧНЫХ СОЕДИНЕНИЙ
Dudas et al. Low molecular weight glycosaminoglycan C3 attenuates AF64A-stimulated, low-affinity nerve growth factor receptor-immunoreactive axonal varicosities in the rat septum
EP4159239A1 (fr) Agent permettant de protéger et/ou de régénérer des jonctions neuromusculaires
CN101076250A (zh) 神经保护性螺甾烯醇药用组合物
Zhang et al. Effect of Donepezil on Vascular Dementia in Rats via PI3K/AKT Pathway
WO2023117990A1 (fr) Utilisation de sels de succinate de n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine et de solvates associés pour le traitement de maladies des motoneurones et de troubles de la jonction neuromusculaire
JP2008534623A (ja) ミトコンドリア障害の治療のためのスピロステノールの使用

Legal Events

Date Code Title Description
FZDE Dead